KNSA (Kiniksa Pharmaceuticals International) Tariff Resilience Score: 7/10 (As of Jul. 04, 2026)


KNSA Kiniksa Pharmaceuticals International PLC KNSA
54 GF Score
Price $64.53
GF Value $48.22
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Kiniksa Pharmaceuticals International Tariff Resilience Score?

Kiniksa Pharmaceuticals International KNSA +2.62% 54 Tariff Resilience Score is 7 as of Jul. 04, 2026. GuruFocus rates KNSA with a GF Score™ of 54/100 and a GF Value™ of $48.22 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,030 Drug Manufacturers companies, Kiniksa Pharmaceuticals International ranks better than 97.09% on this metric.

Kiniksa Pharmaceuticals International has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Kiniksa Pharmaceuticals International has Kiniksa Pharmaceuticals has a global supply chain for drug development but benefits from industry-specific exemptions on medical products. The company can mitigate tariff impacts through strategic partnerships and alternative sourcing, maintaining a moderate resilience to trade disruptions.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Kiniksa Pharmaceuticals International might have Highly Resilient.

Kiniksa Pharmaceuticals International  (NAS:KNSA) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Kiniksa Pharmaceuticals International Tariff Resilience Score Related Terms

KNSA vs INDV, AMRX, RGC: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kiniksa Pharmaceuticals International's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kiniksa Pharmaceuticals International Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kiniksa Pharmaceuticals International's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Kiniksa Pharmaceuticals International's Tariff Resilience Score falls into.


KNSA
54GF Score
Kiniksa Pharmaceuticals International PLC KNSA
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Kiniksa Pharmaceuticals International (KNSA) has a Tariff Resilience Score of 7 as of Jul. 04, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Kiniksa Pharmaceuticals International ranks #30 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Kiniksa Pharmaceuticals International's Tariff Resilience Score too high?
Kiniksa Pharmaceuticals International's current Tariff Resilience Score is 7. Based on the distribution chart, Kiniksa Pharmaceuticals International ranks #30 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kiniksa Pharmaceuticals International has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kiniksa Pharmaceuticals International's Tariff Resilience Score compare to INDV and AMRX?
According to the Drug Manufacturers industry distribution chart, Kiniksa Pharmaceuticals International ranks #30 out of 1030 companies for Tariff Resilience Score. This places Kiniksa Pharmaceuticals International in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Kiniksa Pharmaceuticals International's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiniksa Pharmaceuticals International stock overvalued right now?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International (KNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is $48.22, compared to a current price of $64.53 — trading 33.8% above its estimated fair value. The current Tariff Resilience Score is 7. Kiniksa Pharmaceuticals International's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Kiniksa Pharmaceuticals International (KNSA), the current Tariff Resilience Score is 7 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kiniksa Pharmaceuticals International (KNSA) Overvalued in 2026?

Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued. The current stock price of $64.53 is trading 33.8% above its estimated GF Value™ of $48.22. GuruFocus considers Kiniksa Pharmaceuticals International to be Significantly Overvalued.

Key valuation signals for KNSA:

  • Tariff Resilience Score: 7
  • GF Value™: $48.22 vs. price of $64.53 (33.8% above fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the KNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kiniksa Pharmaceuticals International Business Description

Address 105 Piccadilly, Second Floor, London, GBR, W1J 7NJ
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
54GF Score

Get the complete analysis for KNSA

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$64.53
Price
$48.22
GF Value